Summary.-A total of 107 patients with bronchial carcinoma have been studied for the presence of potential circulating tumour markers which might be used as indicators of recurrence after primary treatment. Plasma carcinoembryonic antigen (CEA) levels were estimated in every patient and, after a preliminary hormone screening study, plasma calcitonin (CT) and parathyroid hormone (PTH) levels were assayed in 66 patients. Oat-cell tumours SUCCESSFUL therapy in malignant disease depends on a correct initial assessment of the extent of spread and then on appropriate treatment to eradicate all the tumour tissue. Treatment may produce a complete remission of symptoms, yet in many cases there is residual tumour, either at the primary site or disseminated widely throughout the body. The ability to detect such tumour masses and suitable means to monitor the progress of treatment are necessary prerequisites for logical therapy.
In cases of bronchial carcinoma (as in many other types of cancer) the malignant cells are located in solid masses forming the primary tumour, or in discrete lymph node or haematogenous metastases, and in addition there may be widely disseminated micrometastases. The large masses may be located by clinical examination or by radiological or isotopic investigations. But the micrometastases can only be detected if they produce substances which can be measured in the peripheral circulation; so-called "tumour markers".
Some of these tumour products are detectable by biochemical methods, and their presence in the plasma may indicate persistence of micrometastases after treatment of the overt tumour masses. The value of such markers can only be determined by measuring the plasma levels before and during treatment of the local disease and during subsequent follow-up. In choriocarcinoma HCG is a specific and almost ideal biochemical marker, whose measurement has led to great advances in treatment of the disease (Bagshawe, 1967) . No ideal marker exists for bronchial carcinoma, but a number of substances have been noted in association with these tumours which may prove useful in planning a therapeutic approach.
Finding a suitable marker is of the utmost importance in an individual case where systemic treatment of micrometastases is contemplated. Particular value of such an approach can be anticipated in cases of oat-cell carcinoma, as these tumours are almost always disseminated at the time of presentation. There is, however, evidence to suggest that the prognosis may be improved by destruction of the main tumour masses by radiotherapy, and chemotherapy for presumed micrometastases (Horwitz et al., 1965; Eagan et al., 1974; Johnson, Brereton and Kent, 1976 (PTH) and calcitonin (CT).
Based on the results of the multiple hormone measurements, the only hormones which showed any promise as tumour markers in bronchial carcinoma were CT and PTH. CT was measured by a radioimmunoassay described in detail elsewhere (Coombes, et al., 1974) . The normal levels of CT are all below the detection limit of this assay (0.1 ,ug/l). PTH was assayed by a modification of the method described by Greenberg et al. (1974) using a human PTH standard. The normal range using this assay is <0-1-0-73 ,ug/l. CT (Hansen et al., 1974) and these non-specific factors may be the cause of the elevation in some cases of bronchial carcinoma. The non-specific causes are, however, unlikely to be the cause of a level in excess of 40 ,ug/l and this level should therefore be regarded as definite evidence of a CEA-producing tumour (Mackay et al., 1974) .
The results obtained here and shown in Tables I and II would in a 57-year-old woman with an oat-cell carcinoma of the bronchus involving local nodes and probably peribronchial tissues. Radiotherapy was started for the primary lesion (3000 rad in 10 fractions) and 5 days later the patient was complaining of nausea, vomiting and pain in the right shoulder, and on examination jaundice and tender hepatomegaly were noted. A liver scan was made and intensive chemotherapy was begun, using a combination of prednisone, 5-fluorouracil, cyclophosphamide and adriamycin and followed up a week later with bleomycin and vincristine. Symptomatic improvement ensued and the liver was noted to be smaller. Radiotherapy was given to the liver (200 rad, followed by 300 rad one month later) and chemotherapy was continued. A repeat liver scan confirmed the diminution in the size of the whole organ and of the cold areas noted on the initial scan. Similarly the chest X-ray showed almost complete resolution of the opacity in the left lung. Both CEA and CT levels were raised prior to treatment, and showed a further increase during her initial radiotherapy. Subsequently there was a marked fall in the levels of both markers (Fig. 3) unexpectedly 2 months after commencing treatment. Post mortem examination revealed that viable tumour tissue was only present in the liver, where none of the nodules was greater than 2-0 cm in diameter.
DISCUSSION
The practical importance of any circulating tumour marker depends on 3 main factors. Firstly, the frequency with which the marker is found in any population of tumour patients; secondly, a good correlation between the marker level and the mass of tumour; and thirdly, the availability of an effective treatment for the malignancy in question.
The importance of marker frequency depends on the way in which it is intended to use the information obtained. If it is intended to use the marker as a screening or diagnostic test, then it must be present in virtually 100% of cases. In this context, Concannon et al. (1974) concluded that CEA is of no value in bronchial carcinoma. Similarly, if the marker is to be applied as a test for disseminated disease, and thus exclude patients who are unsuitable for surgery, it must correlate very closely with the presence of metastases. Although CEA does not meet these requirements, Vincent et at. (1975) have presented good evidence to show that the prognosis is very poor in patients with significantly raised CEA levels who undergo surgery. In this series, 5/7 patients with initial CEA levels above 15 ,ug/l (Hoffmann La Roche) were dead in 5 months, and all were dead within one year.
The correlation between the level of tumour marker and the mass of tumour depends on a number of factors. As indicated in the results section, the CEA levels tended to rise as the disease advanced. However, the plasma level at any one time reflects a balance between production and degradation and it is impossible to say whether there is a precise relationship between the CEA (or CT) level and the tumour mass. The fact that the CEA levels rose in an exponential fashion in some patients (Fig. 1) would suggest that some correlation exists.
In several tumours it has been shown that a suitable marker will detect the presence of disseminated disease which it is impossible to diagnose by other methods. The most notable examples are choriocarcinoma (Bagshawe, 1967; Crawford, 1972) and testicular teratomas in which the measurement of HCG/3 subunit (Cochran et al., 1974; Keogh et al., 1975) has been applied successfully to treatment. Undoubtedly, CEA can detect recurrence of colo-rectal cancer before it becomes clinically apparent, but this association has not had the same impact because chemotherapy is not as effective when these tumours disseminate.
It is possible to ascertain the value of a tumour marker, only when there is a sufficient variety of chemotherapeutic agents and schedules available to permit variations in treatment according to changes in levels of circulating marker substance. Previously, chemotherapy for bronchial carcinoma has not been particularly effective but, more recently, several published series have shown that the prognosis for oat-cell carcinomas may be improved by the use of more radical combinations of radiotherapy and chemotherapy (Eagan et at., 1974; Johnson et al., 1976; Choi and Carey, 1976; Hornback et at., 1976 The cases in which both CEA and CT were measured revealed some interesting differences. The case of oat-cell carcinoma illustrated in Fig. 2 had normal CEA levels throughout, whereas the CT level was abnormal at the onset and showed a dramatic rise with radiotherapy, possibly due to sudden release of stored hormone from regressing tumour tissue. In this patient, chemotherapy was instituted and the CT became undetectable and remained so during follow-up for almost one year. Thus, it would seem that neither CEA nor CT had any potential as markers in this patient, despite the fact that the tumour appeared to be producing and storing CT. However, it must be remembered that the CT radioimmunoassay used in this study does not detect levels of the hormone circulating in normal individuals. The use of a more sensitive assay (Hillyard et al., 1977) in this patient might have shown that the CT level was increasing, yet remaining within the normal range, as the disease progressed. In other cases, as shown in Fig. 3 , both CEA and CT were elevated. In this patient with disseminated oat-cell carcinoma, a treatment programme was planned along the lines suggested by Johnson et al. (1976) . An excellent clinical response was obtained, and this was accompanied by a well marked drop in the levels of CEA and CT.
Clearly CEA and CT are not ideal tumour markers for bronchial carcinoma, but in an individual case where the level of one or other marker is elevated initially, or subsequently rises to abnormal levels, its measurement may prove a valuable aid to therapy. Although the proportion of cases in which this occurs is low, the disease is common, and therefore CEA and CT measurements are of potential use in a large number of patients.
This would be of particular importance in oat-cell tumours, in which CEA levels are frequently elevated and CT levels are abnormal in 75%0 of cases. Further longitudinal studies are required in order to define more precisely the role of these tumour markers in the overall management of bronchial carcinoma. 
